Clinical trial · Interventional
The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma
NCT01908972CI-TRIAL-00036179completedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety and efficiency of Propranolol as an initial treatment for pediatric hemangioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hemangioma | Hemangioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prednisolone | Drug | Prednisolone | ALIAS |
| Propranolol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Prednisolone
- description
- Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks
- interventionNames
- Drug: Prednisolone
- type
- EXPERIMENTAL
- label
- Propranolol
- description
- Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks
- interventionNames
- Drug: Propranolol
Primary outcomes (1)
- measure
- Number of Participants With Clinical Response From Baseline in Hemangioma Volume Measured by MRI or SONO
- timeFrame
- After 16weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 9 Months
Show eligibility criteria text
Inclusion Criteria: * Hemangioma patient ( 0 \~ 9 months old) * No treatment before * 10 \~ 20 % volume increase in 2 \~ 4 weeks * Hemangioma that caused organ function * Hemangioma that will cause aesthetic problem Exclusion Criteria: * Cardiovascular disease (impossible to use propranolol) * Drug adverse reaction or allergy history (propranolol, steroid) * Bradycardia, Atrioventricular block, atrial block * Cardiogenic Shock * Right heart failure (pulmonary hypertension) * Congestive heart failure * Hypotension * Peripheral nerve disease (moderate) * Angina * Hormone deficiency patient * Pulmonary disease (asthma) * diabetic ketoacidosis * laser treatment history
References
Publications (1)
- DERIVEDKim KH, Choi TH, Choi Y, Park YW, Hong KY, Kim DY, Choe YS, Lee H, Cheon JE, Park JB, Park KD, Kang HJ, Shin HY, Jeong JH. Comparison of Efficacy and Safety Between Propranolol and Steroid for Infantile Hemangioma: A Randomized Clinical Trial. JAMA Dermatol. 2017 Jun 1;153(6):529-536. doi: 10.1001/jamadermatol.2017.0250. PMID 28423174